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tran activity dosage was dosed with Hemoclot at the hospital ‘s admission for
bleeding (Table). 
Results: 2/3 of our patients were very old (>80 years). All of our patients
had HAS-BLED score > 4. 2/3 of the patients had impaired renal function
(clearance <60mL/min). All our 3 patients had the serious bleeding event
shortly after the introduction of Dabigatran < 2 months. In the 3 cases, there
was a documented plasma overdose in Dabigatran Etexilate, in parallel with
impairment of renal function concomittent of bleeding. 
Conclusion: Our sample of cases highlights that in some selected frail
population (elderly, high HAS BLED score, moderate impairment of renal
function) dosage of Hemoclot (Anti IIa activity) could be helpfull to under-
stand the bleeding event and a tight follow up of renal function is important,
especially before and during the following weeks after the beginning of the
treatment (table above).
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Percutaneous transcatheter obliteration of prosthetic mitral paraval-
vular leaks
François Bagate, Benoit Gerardin, Olivier Belliard, Remy Pillière, Adèle
Nana
Clinique Ambroise Paré, Cardiologie, Neuilly Sur Seine, France
Introduction: Prosthetic paravalvular leaks (PVL) of biological or
mechanical heart valves implanted surgically are sometimes responsible of
heart failure or hemolysis requiring reoperations, which are often of high risk.
The percutaneous occlusion of these leaks is an alternative treatment. The aim
is to assess the feasibility and efficacy of percutaneous transcatheter oblitera-
tion of paravalvular leaks.  
Methods: 10 patients underwent transcatheter closure of prosthetic mitral
paravalvular leaks from 2009 to 2013 in one center. All patients had symp-
toms of hemolysis and/or severe cardiac failure with high surgical risk. Each
percutaneous transcatheter intervention was guided by three dimensions trans-
esophageal echocardiography (3D TOE) and performed with different kinds of
Amplatzer devices. 
Results: Patients had high operative risk (average logistic EuroSCORE
1=21,76%) mainly because of previous cardiac surgeries (3 times in
2 patients, 2 times in 6 patients and 1 time in 2 patients). Implantation of a
device was impossible in 2 patients without any complication. Implantation of
a device has been technically successful in eight patients (80%):  out of them,
5 (50%) were immediately dramatically improved and remained asymptomatic
in the follow up. In the 3 other patients, 1 had an migration of the prosthesis
into the left atrium without consequence, 1 had few months after on 2 occa-
sions enlarged the leak in spite of 2 new successful implantations of prosthesis
and finally died of heart failure, 1 patient had a severe complication with a
dramatic worsening of the hemolysis on a residual leak leading to death in
spite of the full occlusion of the residual leak with a second device. 
Conclusions: Transcatheter closure of PLV is technically feasible and
facilitated by the 3D TEO and the provision of new devices. Despite the dif-
ficulties, the results of this short series demonstrate that this technique is an
attractive alternative to surgery in these high risks patients.
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Factors predicting mitral restenosis after successful percutaneous
mitral commissurotomy
Leila Bezdah, Emna Allouche, Hbib Ben Ahmed, Slim Sidhom, Hassen
Sammoud, Wejdène Ouechtati, Sami Marouène, Hédi Baccar
Hôpital Charles Nicolle, Cardiologie, Tunis, Tunisie
Introduction:  Percutaneous mitral commissurotomy (PMC) is the alterna-
tive treatment of choice for mitral stenosis (MS). Its immediate and medium
term results are comparable to those of surgical commissurotomy, however in
the long term there is a risk of restenosis. The purpose of this study is to deter-
mine the factors predicting restenosis after PMC.
Methods: 322 patients (66% women), average age: 35 ±13 years (9-75 years)
having a tight MS and treated by PMC with Inoué balloon. The anatomic
aspect of the mitral apparatus before PMC has been studied according to
the criteria of the Wilkins score with a concomitant study of the state of
mitral commissures. The primary success of PMC is defined as follows:
mitral area (MA) post-PMC >1,5 cm2 and gain in MA >25% and mitral
regurgitation (MR) ≤ grade 2. Mitral restenosis is defined as a MA
<1,5 cm2 and/or loss >50% of initial gain in MA.
Results:  The rate of primary success of PMC was 86% and mean MA post
PMC was 1,82±0,33 cm² compared to MA pre-PMC of 1±0,18 cm²
(p <0.0001). Opening of two commissures has been observed in 74% of
patients. After an average period of 62±32 months, only 12% of patients had
a dyspnea stage III-IV of NYHA, MA was 1,64±0.3 cm² (p<0.001) and mitral
restenosis happened in 47 patients (20%) after a period of 60,48±27 months
(22–124 months).
The independent predictors of mitral restenosis after a successful PMC
were: previous surgical commisurotomy, Wilkins score > 8, MA after PMC
<1,8 cm² and absence of bicommissural opening post PMC.
Conclusion: A favorable anatomy of mitral apparatus and the optimisation
of immediate result of PMC are the guaranty for the maintain of good result
in the long term.
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Isolated aortic valve replacement in octogenarians before and after
the introduction of transcatheter aortic valve implantation
Moukda Khounlaboud (1), Erwan Donal (2), Anne Ingels (3), Jean-Philippe
Verhoye (4), Philippe Mabo (1), Hervé Le Breton (1), Alain Leguerrier (4)
(1) CHU Rennes, Département de Cardiologie, Rennes, France – (2) CHU
Rennes – Hôpital Pontchailloux, Rennes, France – (3) CHU Rennes –
Hôpital Pontchailloux, Centre Cardio-Pneumologique, Rennes, France –
(4) CHU Rennes, Rennes, France
Background: Aortic valve stenosis is the most frequently diagnosed val-
vular disease, with an incidence of 5% in octogenarians. The reference treat-
ment was surgical aortic valve replacement. But, since few years, a new
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Abstract 146 – Table – Details of episode of major bleedings in 3 patients taking Dabigatran Etexilate. Anti IIa activity 2-3 hours after the taken pills must be 
between 117-275 ng/ml 
Age Site of bleeding Clearance 
creatininemia
before event
(Cockroft, ml/min)  
Clearance 
at admission
Clearance at discharge Anti IIa activity 
(ng/ml) 
Anti IIa 
discharge 
87 Gastrointestinal 69 44 53 570 190
89 Hematuria 32 16 23 480 200
67 Gastro intestinal 42 29 25 400 110
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alternative treatment appeared, the transcatheter aortic-valve implantation
(TAVI), for high-risk patients.
In our study, we compared preoperative characteristics and prognostic of
elderly patients who underwent to surgery, before and after the coming of the
TAVI.
Methods: We retrospectively included 517 consecutive surgical isolated
aortic valve replacements, performed in our center between the 1st January
2006 and the 31st December 2011, in octogenarians (229 in the group 2006-
2008, 288 in the group 2009-2011) and compared their characteristics and
their follow-up.
Results: The mean (±SD) age was 83±2 years old in the group 2006-2008
and 83.5±2. in the group 2009-2011 (p=0.1). There were no significant differ-
ences for the preoperative characteristics: NYHA status (p=0.4), incidence of
heart failure (p=0.3), left ventricle ejection fraction (59.8±12.2 in the group
2006-2008 versus 59.9±11.3 in the group 2009-2011, p=0.9), arteriopathy of
the lower limbs (p=0.1), chronic renal failure (p=0.3), chronic pulmonary dis-
ease (p=0.4), cancer (p=0.1), previous cardiac surgery (p=0.08). The logistic
EuroSCORE was 7.78±4.60 in the group 2006-2008 and 7.33±3.96 in the
group 2009-2011 (p=0.2). Operative mortality was comparable: 5.2% in the
group 2006-2008 and 6.9% in the group 2009-2011 (p=0.4).
Conclusion: Despite the coming of TAVI, in our experience, population of
patients aged over 80 years-old who underwent to surgical aortic valve
replacement remains similar and operative mortality remains stable. 
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Aortic valve calcium score is a strong predictor of mortality after
TAVI
Franck Goïorani (1), Sébastien Molière (2), Soraya El-Ghannudi (1),
Sebastien Hess (1), Antje Reydel (1), Bogdan Radulescu (1), Laurence
Jesel (3), Mi Jeung (2), Catherine Roy (2), Patrick Ohlmann (4), Olivier
Morel (1)
(1) NHC, Pôle d'activité médico-chirurgicale cardiovasculaire, Stras-
bourg, France – (2) NHC, Pôle d'Imagerie, Strasbourg, France –
(3) Hôpitaux Universitaires de Strasbourg, Strasbourg, France –
(4) Hôpitaux Universitaires de Strasbourg, Fédération de Cardiologie,
Strasbourg, France
Background: TAVI is an novel therapy for patients with symptomatic
severe aortic stenosis with contra-indications to surgical valve replacement.
However, traditionnal risk scores  for surgical valve replacement such as
Euroscore failed to accurately estimate the outcome following TAVI proce-
dure and alternate predictive factors are needed. 
In this study, we sought to investigate whether the CT derived aortic valve
calcification score or the aorta ascendent calcification score could be usefull
tools in the prediction of adverse outcome following TAVI implantation using
CoreValve or Edwards Sapien valve.
Methods: Consecutive patients treated with CoreValve or Edward Sapien
valve were enrolled in a monocentric study. Aortic valve calcium score and
ascendens aorta calcium score were calculated using pre-procedural 64 slices
ECG gated CT scans.
Results: 44 patients (21 male, 23 female), 85±4 yr  old with a mean
Euroscore of 25±9 were consecutively enrolled. Baseline LVEF was at
52±14% with a mean gradient of 51±14 mmHg and an  indexed aortic
valve area of 0.36±0.11 cm2/m2. One month and 6 month mortality were
respectively of 18%  and 25%. Elevated valve calcium score was evi-
denced in non-survivors (5594±2182 vs 3806±1366). Conversely, other
parameters such as ascendens aorta calcium score, Euroscore, LVEF,
NYHA class failed to predict adverse outcome. At 6 month, survival was
of 84.4% in patients with calcium valve score <5193 (<75th percentile)
and of 15.6% in patients  with calcium valve score >5193 (>75 th percen-
tile). In multivariate analysis, calcium aortic valve score >5193 was a
strong predictor of 1 and 6 month mortality.
Conclusion: Calcification of the aortic valve appears to be  a strong pre-
dictor of 1 and 6 month mortality following TAVI procedures and could be a
useful parameter in patients selection and risk determination.
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Baseline NT-proBNP and the impact of aortic regurgitation after
transcatheter aortic valve implantation
Bogdan Borz (1), Eric Durand (1), Matthieu Godin (1), Christophe Tron (1),
Camille Hauville (1), Alexandre Canville (1), Pierre-Yves Litzler (2),
Jean-Paul Bessou (2), Alain Cribier (1), Hélène Eltchaninoff (1)
(1) CHU Charles Nicolle, Cardiologie, Rouen, France – (2) CHU Charles
Nicolle, Chirurgie Cardiaque, Rouen, France
Background: Aortic regurgitation (AR) is an important complication of
transcatheter aortic valve implantation (TAVI) and even moderate AR is asso-
ciated with increased mid-term mortality after TAVI. This association with
decreased survival is poorly explained.
Objective: We sought to analyse the impact of AR on mortality after
TAVI as a function of baseline NT-proBNP (NTBNP). 
Methods: We included 236 consecutive patients from our single centre
registry, all implanted with the Edwards valve, via the transfemoral route. AR
severity was evaluated by transthoracic echocardiography. NTBNP was mea-
sured 24 hours before implantation and patients were divided in 2 groups
according to the median NTBNP value.
Results: Median age was 85 years (IQR:80-89) and 137 (58%) were
women. Patients with low NTBNP had higher left ventricular ejection frac-
tion: 63% (55-70) vs. 52% (35-65), p<0.001, smaller telediastolic diameters:
52 mm (46-56) vs. 56 mm (49-61), p=0.01, less severe aortic stenosis:
0.70±0.2cm2 vs. 0.62±0.15cm2, p<0.001, but a similar mean aortic gradient:
45±15 mmHg vs. 46±20 mmHg, p=0.58. Pre-procedural moderate or severe
AR (26% vs. 42%, p=0.013) and mitral regurgitation (36% vs. 56%, p=0.004)
were less common in the low NTBNP group. After TAVI, moderate or severe
AR occurred in 26% of patients and was significantly associated with
increased 2-year mortality only in the low NTBNP group (Figure next page).
Conclusion: Moderate or severe AR after TAVI was associated with
increased 2-year mortality only in patients with low baseline NTBNP. Our
data suggest that the impact of AR after TAVI is absent in patients with more
severe aortic stenosis and more frequent pre-procedural AR or mitral regurgi-
tation (figure next page).
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Comparison of two antiplatelet therapy strategies in patients under-
going transcatheter aortic valve replacement: is dual antiplatelelet
therapy mandatory?
Eric Durand (1), Didier Blanchard (1), Stephan Chassaing (2), Bogdan
Borz (3), Antoine Lafont (1), Olivier Bar (2), Matthieu Godin (4), Chris-
tophe Tron (4), Rachid Zegdi (5), Didier Chatel (6), Olivier Le Page (6),
Pierre Yves Litzler (7), Jean Paul Bessou (7), Nicolas Danchin (1), Alain
Cribier (3), Hélène Eltchaninoff (3)
(1) Hôpital Européen Georges Pompidou (HEGP), Cardiologie, Paris,
France – (2) Clinique Saint Gatien, Cardiologie, Tours, France – (3) Uni-
versity Hospital of Rouen, Hospital Charles Nicolle, Cardiologie et
INSERM UMR 1096, Rouen, France – (4) University Hospital of Rouen,
Hospital Charles Nicolle, Cardiologie, Rouen, France – (5) Hôpital Euro-
péen Georges Pompidou (HEGP), Chirurgie Cardiaque, Paris, France –
(6) Clinique Saint Gatien, Chirurgie cardiaque, Tours, France – (7) Uni-
versity Hospital of Rouen, Hospital Charles Nicolle, Chirurgie cardiaque
et INSERM UMR 1096, Rouen, France
Objectives: To compare the risk/benefit ratio of two antiplatelet therapy
strategies in patients undergoing transcatheter aortic valve replacement
(TAVR).
Background: Dual antiplatelet therapy is commonly used in patients
undergoing TAVR. However, the optimal antiplatelet regimen following
TAVR is uncertain and remains to be determined.
Methods: We prospectively evaluated 2 strategies of antiplatelet therapy in
362 consecutive patients included in 3 centers from the FRANCE 2 TAVR
registry between January 2010 and December 2011. Patients treated by the
combination of aspirin and clopidogrel before TAVR were excluded (n=70).
A strategy using mono antiplatelet therapy (Group A, n=164) was compared
© Elsevier Masson SAS. All rights reserved.
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to a strategy using dual antiplatelet therapy (Group B, n=128). The primary
end point was a combination of mortality, major stroke, life-threatening
bleeding (LTB), myocardial infarction, and major vascular complication at
30 days. All adverse events were adjudicated according to the Valve Aca-
demic Research Consortium.
Results: The primary end-point occurred in 22 patients (13.4%) in the group
A and in 30 patients (23.4%) in the group B (p=0.026). LTB and major bleedings
occurred less frequently in group A compared to group B (3.7% vs. 12.5%,
p=0.005; 2.4% vs. 13.3%, p<0.0001; respectively). The lower risk of the strategy
using mono versus dual antiplatelet therapy persisted after multivariate adjustment
and propensity score-analysis (HR 0.53; 95% CI 0.28-0.95; p=0.033).
Conclusions: A strategy using mono versus dual antiplatelet therapy fol-
lowing TAVR is associated with improved outcomes in patients who under-
went TAVR. The results of our study question the justification of dual
antiplatelet therapy, and require confirmation in a randomized trial.
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Feasibility of percutaneous mitral commissurotomy in patients with
commissural mitral valve calcifications
Julien Dreyfus , C. Cimadevilla, Eric Brochet, D. Himbert, Bernard Iung,
Alec Vahanian, David Messika-Zeitoun
Hôpital Bichat-Claude Bernard, Cardiologie, Paris, France
Mitral valve calcifications, especially located in the commissural area, are
often considered as a relative contra-indication to percutaneous mitral com-
missurotomy (PMC). We sought to evaluate in a large series of patients with
mitral stenosis (MS), PMC results according to the degree and location of
mitral valve calcifications.
Over a 3 years period, all consecutive patients who underwent a PMC
at our institution were enrolled in the present study. Calcifications were
assessed using transthoracic echocardiography and defined as bright areas
with echocardiographic shadowing. According to the distribution of calci-
fications (within the valves leaflets’ or at the commissural level) and the
degree of calcification (independently scored for each commissure from 0
– absent – to 3 – severe –), 3 groups were defined: group 1=no calcifica-
tion, group 2 = leaflets’ calcifications but no significant commissural cal-
cifications and group 3 = at least one calcified commissure of grade ≥2.
Patients with severe bilateral calcifications were excluded from PMC. A
good immediate PMC result was defined as a final valve area ≥1.5 cm²
with no mitral regurgitation >2/4.
We enrolled 464 patients. Patients in group 2 and 3 were older, presented
more often in atrial fibrillation and with more severe MS than patients in
group 1. PMC success rate decreased from group 1 to 3. However, a complete
opening of at least one commissure was achieved similarly in the 3 groups and
in group 3 the calcified commissure could be totally split in 40%.
In this large series of patients with MS we showed that a successful PMC is
obtained less frequently in patients with calcified commissures but a successful
PMC can still be achieved in a large proportion of patients and the calcified com-
missure can be split in more than one third of patients. Our results support the use
of PMC as a first line treatment of patients with severe MS even in the presence
of commissural calcifications if clinical characteristics are favorable (table on next
page). 
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Emergent balloon mitral valvotomy in pregnant women presenting
with refractory pulmonary edema
Majed Hassine , Fatma Ben Amor, Nidhal Bouchahda, Ibtihel Mechri,
Marouen Mahjoub, Zohra Dridi, Fethi Betbout, Habib Gamra
Hôpital Fattouma Bourguiba, Service de cardiologie A, Monastir, Tunisie
Background: Mitral stenosis is the most common valvular heart lesion
found in pregnancy. When severe, it leads to significant risk of mortality for
both mother and fetus.The role of balloon mitral valvotomy (BMV) in such
patients is ill-defined.
Objectives: We sought to evaluate the feasibility, efficacy and safety of
emergent BMV in pregnant patients with refractory pulmonary edema and to
determine maternal and fetal outcome.
Methods: Of 88 patients undergoing BMV during pregnancy from January
1990 to December 2011. 28 women were in New York Heart Association func-
tional class IV and underwent emergent BMV. During the procedure, radiation
exposure was minimized by means of total abdominal and pelvic shielding.
Results: The mothers's mean age at the time of BMV was 28, 86±5,
7 years, and the gestation period was 30±5,1 weeks. Mitral valve (MV) was
assessed using the Wilkins score which averaged 7,4± 1,8 (range 4 to 14). Flu-
oroscopy time was 7.8+/-1.9 minutes.
The BMV procedure was successful in 25 (89, 3%) patients with a dra-
matic improvement in patient symptoms. 
The mitral valve area increased from 0.8+/-0.2cm2 to 2,2±0,42 cm2
(p<0.0001). The mitral valve pressure gradient decreased from 22,2±9,3 to
5,7±4 mmHg (p<0.0001). The left atrial pressure decreased from 29,4±9,3 to
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15,4±7,3 mmHg (p<0.0001). The pulmonary artery pressure decreased from
58,8±21,1 to 37,2±14,3 mmHg (p<0.0001).
One patient developed severe mitral regurgitation and required urgent
mitral valve replacement. There was no maternal mortality or significant foetal
morbidity. 
Pregnancy was uneventful in all patients, all babies were born at full term
by spontaneous vaginal delivery in 24 cases (85,7%) and by cesarian section
for obstetrical reasons in 4 (14,3%), with no obvious malformations. None of
the babies needed intensive care monitoring. The average Apgar scores at
1 min were 8,6±1. The mean birth weight was 3,1 Kg.
Conclusion: During pregnancy, emergent BMV is safe and feasible in
patients with symptomatic mitral stenosis and severe pulmonary edema. There
is marked symptomatic relief, along with excellent maternal and fetal out-
comes.
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Long-term outcomes after transcatheter aortic valve implantation – a
Rouen study
Eric Durand (1), Bogdan Borz (2), Matthieu Godin (3), Christophe Tron
(3), Pierre Yves Litzler (4), Jean Paul Bessou (4), Fabrice Bauier (2),
Alain Cribier (2), Hélène Eltchaninoff (2)
(1) Hôpital Européen Georges Pompidou (HEGP), Cardiologie, Paris,
France- (2) University Hospital of Rouen, Hospital Charles Nicolle, Car-
diologie et INSERM UMR 1096, Rouen, France – (3) University Hospital
of Rouen, Hospital Charles Nicolle, Cardiologie, Rouen, France –
(4) University Hospital of Rouen, Hospital Charles Nicolle, Chirurgie car-
diaque et INSERM UMR 1096, Rouen, France
Background: Transcatheter aortic valve implantation (TAVI) has become
an alternative to medical therapy in non-operable patients and appears compa-
rable to surgery in high-risk patients. However, long-term durability and out-
comes after TAVI has been poorly evaluated.
Methods: Between april 2002 and december 2008, 105 consecutive
patients underwent TAVI for the treatment of aortic stenosis in our institution
including compassionate implantations in 41 patients with end-stage aortic ste-
nosis and no surgical options. Patients who died within 30 days were excluded
from analysis, leaving a total of 87 patients implanted with the balloon
expandable Cribier-Edwards (n=49) or Edwards SAPIEN (n=38) prosthesis.
Access was transfemoral (n=52, 59.8%), transeptal (n=27, 31.0%), or trans-
apical (n=8, 9.2%).
Results: Mean age and logistic EuroSCORE were 81.1±8.0 years and
27.4±14.0%, respectively. Mean aortic valve gradient decreased from
38.8±14.0 mmHg to 9.3±2.5 mmHg after TAVI and 9.2±3.4mmHg at 2 years.
Mean aortic valve area increased from 0.61±0.22 cm2 to 1.71±0.29 cm2 after
TAVI and 1.72±0.25 cm2 at 4 years. After TAVI, 36.8% of patients had para-
valvular regurgitation (PAR) > grade II. PAR was > grade II at 1 to 4 years in
16.1%, 13.6%, 8.0%, and 4.5% of patients, respectively. Up to 4 years, no
patient had prosthetic valve failure. Survival rates at 1 to 4 years were 71%,
57%, 45%, and 32%, respectively. Median survival time after TAVI was
2.95 years (95% CI:1.55-3.64).
Conclusions: The results of our study suggest favorable long-term out-
comes and the absence of valve deterioration up to 4 years after TAVI using
the balloon expandable Edwards prosthesis.
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Predictors of 6-months poor outcomes after transcatheter aortic valve
implantation
Vincent Auffret (1), Marc Bedossa (1), Dominique Boulmier (1), Erwan
Donal (1), Marcel Laurent (1), Jean-Philippe Verhoye (2), Hervé Le Bre-
ton (1)
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(2) CHU Rennes, Chirurgie cardiaque thoracique et vasculaire, Rennes,
France
Background: Patients’ selection for transcatheter aortic valve implantation
(TAVI) remains a major concern. Indeed, despite promising results, it is still
unclear which patients are the most and least likely to benefit from this pro-
cedure.
Methods: Patients who were discharged from our institution with a trans-
catheter-implanted aortic valve were prospectively followed. Our population
was divided into 2 groups, “good outcomes” and “poor outcomes”, according
to the occurrence of the primary endpoint which was the composite of all-
cause death at 6 months, hospitalization for acute heart failure (HF), acute cor-
onary syndrome or stroke and a 6-months New York Heart association func-
tional class III or IV. The patients’ characteristics were studied to find
predictors of poor outcomes.
Results: We included 163 patients (mean age: 80±9 years, 90 male (55%)).
Their mean logistic Euroscore was 18.4±11.4%. Atrial fibrillation (AF) was
present in 44% of patients and baseline systolic pulmonary pressure ≥60
mmHg in 22%. The primary endpoint occurred in 49 patients (mean age:
83±5 years, 31 male (63%)). On multivariate analysis, AF (OR=4.72, 95%CI:
1.80-12.35, p=0.002), baseline systolic pulmonary pressure ≥60 mmHg
(OR=8.35, 95% CI: 2.57-27.15, p<0.001), right ventricle dysfunction
(OR=4.19, 95%CI: 1.31-13.45, p=0.02), baseline aortic regurgitation <2/4
(OR=16.59, 95%CI: 3.41-80.69, p=0.001) and postoperative acute HF
(OR=18.83, 95%CI: 3.59-98.80, p=0.001) were independent predictors of
poor outcomes.
Conclusion: Patients with cardiac comorbidities suggesting a more
evolved aortic stenosis are more likely to present poor outcomes. Our
study highlights the need of a specific “TAVI Risk Score” developed from
large multicenter registries which could lead to a better selection of
patients. Besides, for the first time, we stressed the potential “protective”
effect of at least moderate baseline aortic regurgitation (table on next
page).
Abstract 153 – Table. Results
All patients (464) Group 1 (261) Group 2 (139) Group 3 (64) p
Before PMC
Age, years 54±15 49±15 61±13 58±14 <0.001
Women, % 360 (78) 211 (81) 106 (76) 43 (67) 0.07
Atrial fibrillation, % 143 (31) 61 (23) 56 (40) 26 (41) <0.001
Valve area, cm2 1.06±0.22 1.1±0.22 1.05±0.20 0.95±0.24 <0.001
After PMC
Valve area, cm2 1.76±0.27 1.83±0.26 1.71±0.26 1.61±0.23 <0.001
Mitral regurgitation >2, % 45 (10) 26 (10) 14 (10) 5 (8) 0.86
Good immediate results, % 384 (83) 229 (88) 108 (78) 47 (73) 0.004
≥ 1 commissure totally split, % 566 (61) 319 (61) 175 (63) 72 (56) 0.14
Data presented are number of patients (percent) or mean±SD
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Vascular complications after TAVI using an exclusive surgical femo-
ral access strategy: a monocenter registry 
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Gandet (3), Bernard Albat (3), Jean-Christophe Macia (1), Guillaume
Cayla (4), Florence Leclercq (1)
(1) Cardiologie A, Montpellier, France – (2) DIM, Montpellier, France –
(3) Chirurgie cardiaque et thoracique, Montpellier, France – (4) Cardio-
logie, Nîmes, France
Background: Major vascular complications (MVC) after transfemoral (TF)
transcatheter aortic valve implantation (TAVI) are frequent, concerning almost
15% of patients associated with unfavorable clinical outcomes. While a percuta-
neous closure of the femoral access site is usually used, no data are currently avail-
able concerning the incidence of MVC with a surgical vascular approach.
Objective: The objective of our study was to assess the incidence of vas-
cular complications (VC) associated with TAVI when an exclusive surgical
strategy is used for the access of the femoral site.
Methods: The study was a monocenter registry conducted at Montpellier
University hospital and included all consecutive patients who had a TAVI pro-
cedure between 2010-2011.We evaluated all complications related to the inter-
vention. VC were classified as major and minor according to the VARC
(Valve Academic Research Consortium) definition. Statistical bilateral signif-
icance threshold was set at 5%. 
Results: The study enrolled 155 patients. The median age was 84 years
(IQR=79-87), the median Euroscore was 18% (IQR=13.6-27), 30.9% (n=34)
were diabetics and 49.2% (n=31) were treated with a double antiplatelet
therapy (APT). The access site was transfemoral for 128 (83%) patients and
an Edwards sapiens prothesis was used for 85% (n=131). 
VC on the access site occured in 9.5% of patients (n=12), 1.5% major
(n=2) and 8% minor (n=10) whereas on the percutaneous controlateral
access, the incidence of VC was 8% (n=12), 2% major (n=3) and 6% minor
(n=9).
Diabetics patients tended to have more VC (43% vs 28% for non-diabetics
p=0.19). Complications were more frequent when patients had a double APT
vs simple (83% vs 42% respectively, p=0.02). 
The other complications were conduction diseases 16% (n=25), kidney
failure 11% (n=18), heart failure 3% (n=5) and stroke 2% (n=3). Three-
months mortality was 9.52% (n=4)
Conclusion: With a strategy of exclusive surgical vascular access used
in our center between 2010 and 2011, the incidence of MVC after TAVI is
very low (1.5%). In our study, the only independent factor for VC was the
double APT. These preliminary results have to be confirmed in a prospec-
tive study.
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QRS duration after TAVI with self expanding bioprosthesis: a useful
tool to predict permanent pacemaker implantation requirement
Gauthier Mouillet , Ronan Deballon, Nicolas Lellouche, Romain Gallet,
Delphine Hayat, Stephane Champagne, Jean Paul Couëtil, Jean Luc
Monin, Jean Luc Dubois-Rande, Emmanuel Teiger
CHU Henri Mondor, Cardiologie, Créteil, France
Background: In a retrospective study, a cut-off value of less than 120 ms
for QRS duration (QRSd) have been proposed to exclude patient requiring
PPM. The purpose of the study was to prospectively evaluate a 12-Lead-EKG
guided approach allowing an early removal of temporary pacing catheter using
QRSd predictor.
Abstract 156 – Table. Multivariate Analysis
Predictors Odds ratio CI p-value
Predictors of 6-months poor outcomes
Atrial fibrillation 4.72 1.80-12.35 0.002
Right ventricle dysfunction 4.19 1.31-13.45 0.02
Severe pulmonary hypertension (sPAP ≥ 60 mmHg) 8.35 2.57-27.15 <0.001
Postprocedural acute heart failure 18.83 3.59-98.80 0.001
No or mild preoperative aortic valve regurgitation 16.59 3.41-80-69 0.001
Predictors of 6-months all-cause mortality
Severe pulmonary hypertension (sPAP ≥60 mmHg) 5.81 1.004-33.67 0.05
Previous balloon aortic valvuloplasty 22.27 2.44-203.34 0.006
Baseline aortic permeability index 0.75 0.59-0.96 0.022
Predictors of acute heart failure after hospital discharge
No or mild preoperative aortic valve regurgitation 49.26 4.06-598.09 0.002
Right ventricle dysfunction 38.34 7.79-188.73 <0.001
Severe pulmonary hypertension (sPAP ≥60 mmHG) 15.75 3.58-69.25 <0.001
Acute kidney injury Rifle stage 2 or 3 10.51 1.25-88.37 0.03
Predictors of NYHA functionnal class > 2 at 6 months
Atrial Fibrillation 6.81 1.66-27.96 0.008
No or mild preoperative aortic valve regurgitation 12.20 1.28-116.17 0.03
Moderate or severe preoperative mitral regurgitation 5.91 1.41-24.72 0.02
Baseline aortic mean gradient 0.94 0.89-0.98 0.009
Moderate or severe preoperative mitral regurgitation 8.97 1.94-41.56 0.005
New permanent pacemaker 30.73 3.98-237.10 0.001
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Methods: Patients without previous PPM were prospectively included for
TAVI in our center between December 2010 and January 2013. Immediately
after the index procedure,12-Lead EKG was performed:Patients with high
degree AVB were assigned to early PPM group and removed from analysis
(group 1). Patients with QRSd< 120 ms were assigned to early pacing catheter
removal group (group 2) and patients with QRSd≥120 ms were assigned to
temporary pacing catheter and continuous EKG monitoring in ICU (group3).
Results: A total of 194 patients (age 85±6 years; female sex: 58%) were
included. A 12-Lead-EKG was performed immediately after TAVI: 21 (10%)
patients presented acute high degree AVB and were assigned to group 1.
Among 173 patients without immediate AVB, 43 (24%) patients had QRSd
<120 ms, 130 (66%) patients had QRSd ≥120 ms and were assigned to group
2 and 3 respectively. After a mean follow-up of 187±222 days, none patient
of Group 2 had PPM implantation. Among 130 patients of Group 3,
40 patients experienced PPM implantation. The patients who exhibited
delayed AVB had significantly wider QRSd (158±17 ms vs. 128±25 ms,
P<0.0001), with no difference in baseline. According to multivariate analysis,
QRSd was the best predictor of PPM after TAVI with HR =1.321 95% CI
(1.055; 1.654) p=0.02. Receiving Operating Characteristics analysis confirmed
that QRSd <120 ms was the optimal cut-off value with 100% of sensitivity to
identify patient without PPM requirement.
Conclusion: QRS duration after TAVI is the best predictor to identify
patient with delayed AVB. QRSd <120 ms is a safety cut-off that allow early
removal of pacing catheter resulting in early discharge from ICU.
